TY - JOUR
T1 - Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
AU - Viale, Giuseppe
AU - Regan, Meredith M.
AU - Mastropasqua, Mauro G.
AU - Maffini, Fausto
AU - Maiorano, Eugenio
AU - Colleoni, Marco
AU - Price, Karen N.
AU - Golouh, Rastko
AU - Perin, Tiziana
AU - Brown, R. W.
AU - Kovács, Anikó
AU - Pillay, Komala
AU - Öhlschlegel, Christian
AU - Gusterson, Barry A.
AU - Castiglione-Gertsch, Monica
AU - Gelber, Richard D.
AU - Goldhirsch, Aron
AU - Coates, Alan S.
PY - 2008/2
Y1 - 2008/2
N2 - Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies.
AB - Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies.
UR - http://www.scopus.com/inward/record.url?scp=39149102890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39149102890&partnerID=8YFLogxK
U2 - 10.1093/jnci/djm289
DO - 10.1093/jnci/djm289
M3 - Article
C2 - 18230798
AN - SCOPUS:39149102890
VL - 100
SP - 207
EP - 212
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 3
ER -